Institute of Food Research
Norwich, Norfolk, NR4 7UA, United Kingdom
NCT Number: NCT00279812
The aim of the study is to investigate the relationship between dose and form of selenium on immune function, and to identify functional markers of selenium status.
Looking for future studies?
Notify Me50 year–64 year
All sexes
Interventional
Not applicable
Norwich, Norfolk, NR4 7UA, United Kingdom
One of the proposed consequences of marginal selenium status is impaired immune function. Establishing the potential role of selenium as an enhancer of immune response in vivo may provide evidence-base for public health policy, with important consequences for preventing influenza and similar diseases in the elderly.
The project consists of a placebo controlled selenium supplementation study and a dietary intervention with un-enriched and selenium enriched onions. In a parallel group design, subjects will be given either one of three doses of Selenomethionine (50, 100 or 200µg selenium/day) or a placebo per day or selenium enriched or un-enriched onions (in the form of test meals) for 12 weeks. Changes in the expression of Se-responsive genes and proteins in blood will be measured and compared with changes in plasma Se concentration and selected selenoproteins. The relationship between dietary Se intake and systemic and mucosal immune responses to influenza vaccine will be examined. Changes in immune cell populations and the influence of Se on NK and CD8 cytotoxicity will be determined by flow cytometry.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Selenomethionine supplement (50ug/d Se) for 12 weeks
Selenomethionine supplement (100ug/d Se) for 12 weeks
Selenomethionine supplement (200ug/d Se) for 12 weeks
3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
Placebo supplement for 12 weeks
Time frame: 12 weeks
Total glutathione peroxidase 1 activity in platelets after supplementation
Time frame: 10 weeks
Plasma selenium concentration after supplementation
Time frame: 10 weeks
Plasma selenoprotein P after the supllementation
Quadram Institute Bioscience
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details